阿立哌唑
帕潘立酮棕榈酸酯
帕利哌酮
医学
精神分裂症(面向对象编程)
中止
危险系数
优势比
利培酮
内科学
药理学
精神科
置信区间
作者
Francesco Bartoli,Daniele Cavaleri,Tommaso Callovini,Ilaria Riboldi,Cristina Crocamo,Armando D’Agostino,Giovanni Martinotti,Federico Bertolini,Giovanni Ostuzzi,Corrado Barbui,Giuseppe Carrà
标识
DOI:10.1016/j.psychres.2022.114405
摘要
In this prospective study, we assessed the effectiveness and acceptability of paliperidone palmitate 1-month (PP1M) and aripiprazole monohydrate (AM) over 1-year follow-up. We included 195 subjects (117 treated with PP1M and 78 with AM) with schizophrenia spectrum disorders from real-world settings. We estimated no differences in hospitalization (Odds Ratio=1.59; p = 0.12), symptoms improvement (p = 0.90 adjusted for baseline severity), and discontinuation (Hazard Ratio=0.72; p = 0.20) at study endpoint. Although current evidence suggests the possible superiority of AM over PP1M, our findings showed comparable effectiveness between these drugs. Additional studies in real-world settings with direct comparisons between these two LAIs are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI